Literature DB >> 10405942

Spondyloarthropathy in the community: clinical syndromes and disease manifestations in Alaskan Eskimo populations.

G S Boyer1, D W Templin, A Bowler, R C Lawrence, S P Heyse, D F Everett, J C Cornoni-Huntley.   

Abstract

OBJECTIVE: To define the clinical spectrum and disease manifestations of spondyloarthropathy (SpA) as seen in a community, rather than a referral setting.
METHODS: Eighty percent (83/104) of all individuals identified as having SpA in a community wide epidemiologic study of Alaskan Eskimos and 83 age and sex matched controls from the same regions participated in a 5 year clinical study. The study included baseline and followup interviews, physical, radiographic, and electrocardiographic examinations, record reviews, and functional assessment. The medical records of an additional 83 age and sex matched controls were reviewed and followed over the same 5 year period.
RESULTS: The spectrum of disease varied from very mild undifferentiated SpA (USpA) to incapacitating ankylosing spondylitis (AS). Most cases were mild. Overlapping clinical features were common in the different syndromes; 10% of the cases met more than 1 set of disease criteria. Axial signs and symptoms were more frequent in patients with AS, but occurred in over half of the patients with USpA and reactive arthritis (ReA) also. Peripheral joint involvement was noted in 85% of the AS cases, usually early in the course of disease. The patterns of joint involvement and enthesopathy were similar in SpA subjects with different syndromes and significantly different from those in control subjects. Patients with AS had a higher frequency of uveitis and of aortic root disease than patients with other syndromes.
CONCLUSION: The results illustrate the extent of shared clinical features in the different SpA syndromes, and describe the frequency of different features associated with SpA in patients and matched controls in a community setting. ReA and USpA were more prevalent and less severe than AS in these populations.

Entities:  

Mesh:

Year:  1999        PMID: 10405942

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  8 in total

Review 1.  Clinical observations programme in SpA: disease parameters, treatment options and practical management issues.

Authors:  Dirk Elewaut; Filip Van den Bosch; Gust Verbruggen; Filip de Keyser; Bert Vander Cruyssen; Herman Mielants
Journal:  Rheumatol Int       Date:  2008-09-26       Impact factor: 2.631

2.  Ankylosing spondylitis and undifferentiated spondyloarthritis in Kuwait: a comparison between Arabs and South Asians.

Authors:  S S Uppal; Mini Abraham; R I Chowdhury; Rakesh Kumari; E M Pathan; A Al Rashed
Journal:  Clin Rheumatol       Date:  2005-10-21       Impact factor: 2.980

3.  Coexisting ankylosing spondylitis and gouty arthritis.

Authors:  Huei-Huang Ho; Kuang-Hui Yu; Ji-Yih Chen; Ja-Liang Lin; Yeong-Jian Jan Wu; Shue-Fen Luo; Lieh-Bang Liou
Journal:  Clin Rheumatol       Date:  2007-03-14       Impact factor: 2.980

4.  Epidemiology of spondyloarthritis in North America.

Authors:  John D Reveille
Journal:  Am J Med Sci       Date:  2011-04       Impact factor: 2.378

5.  Chlamydiae as etiologic agents in chronic undifferentiated spondylarthritis.

Authors:  John D Carter; Hervé C Gérard; Luis R Espinoza; Louis R Ricca; Joanne Valeriano; Jessica Snelgrove; Cynthia Oszust; Frank B Vasey; Alan P Hudson
Journal:  Arthritis Rheum       Date:  2009-05

Review 6.  Undifferentiated spondyloarthritis: a global perspective.

Authors:  Rubén Burgos-Vargas
Journal:  Curr Rheumatol Rep       Date:  2007-10       Impact factor: 4.592

7.  The assessment of the spondyloarthritis international society concept and criteria for the classification of axial spondyloarthritis and peripheral spondyloarthritis: A critical appraisal for the pediatric rheumatologist.

Authors:  Ruben Burgos-Vargas
Journal:  Pediatr Rheumatol Online J       Date:  2012-05-31       Impact factor: 3.054

Review 8.  Systematic review of rheumatic disease phenotypes and outcomes in the Indigenous populations of Canada, the USA, Australia and New Zealand.

Authors:  Kelle Hurd; Cheryl Barnabe
Journal:  Rheumatol Int       Date:  2016-12-17       Impact factor: 2.631

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.